Norwegian biotechnology company Clavis Pharma was spun out of Norsk Hydro in August 2001 to commercialize Lipid Vector Technology (LVT). LVT conjugates fatty acids to existing therapeutics to improve their ability to enter target cells. Clavis' first product is an LVT derivative of Ara-C, a common chemotherapy for blood cancers, which the firm is testing in solid tumor indications.

In Vivo briefly summarizes the technologies of these recently founded companies: AgaMatrix Inc., BioMark Diagnostics Inc., CareX SA, ConPharma AS, GenPath and Nanoplex Technologies Inc.